In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics Inc (NASDAQ: GTHX), with a price target of $79. The company’s shares opened today at $67.95, close to its 52-week high of $69.57.
According to TipRanks.com, White is a 5-star analyst with an average return of 23.6% and a 51.2% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
Currently, the analyst consensus on G1 Therapeutics Inc is a Strong Buy with an average price target of $79.50, implying a 17.0% upside from current levels. In a report issued on September 10, BTIG also initiated coverage with a Buy rating on the stock with a $80 price target.
.
See today’s analyst top recommended stocks >>
Based on G1 Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.87 million. In comparison, last year the company had a GAAP net loss of $15.19 million.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage pharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
